Fig. 2From: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterChanges in peripheral blood mononuclear cell (PBMC) populations. Percentage of indicated cell type in patients treated with sotigalimab, cabiralizumab and nivolumab at cycle 1, day 1 (C1D1), cycle 1, day 2 (C1D2) and cycle 2, day 1 (C2D1). ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001Back to article page